Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Zi-Yi Xu & Jun-Ling Li. (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets and Therapy 12, pages 5467-5484.
Read now
Read now
Vidya H Veldore, Anuradha Choughule, Tejaswi Routhu, Nitin Mandloi, Vanita Noronha, Amit Joshi, Amit Dutt, Ravi Gupta, Ramprasad Vedam & Kumar Prabhash. (2018) Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. Lung Cancer: Targets and Therapy 9, pages 1-11.
Read now
Read now
Yijun Xu, Vivianne W Ding, Hong Zhang, Xun Zhang, David Jablons & Biao He. (2016) Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Therapeutics and Clinical Risk Management 12, pages 807-816.
Read now
Read now
Feliciano Barron, Martha de la Torre-Vallejo, Rosa Luz Luna-Palencia, Andres F Cardona & Oscar Arrieta. (2016) The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety 15:11, pages 1563-1572.
Read now
Read now
Neva Bojovic, Valérie Sabatier & Stephane Rouault. (2015) What innovative business models can be triggered by precision medicine? Analogical reasoning from the magazine industry. Innovation and Entrepreneurship in Health 2, pages 81-94.
Read now
Read now
Mazen Zaarour, Chanudi Weerasinghe, Bassel Nazha, Samer Hassan & Jean-Paul Atallah. (2015) Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. Expert Review of Anticancer Therapy 15:11, pages 1327-1336.
Read now
Read now
Monika Joshi, Syed M Rizvi & Chandra P Belani. (2015) Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Management and Research 7, pages 75-82.
Read now
Read now
Robert G. Mennel. (2015) Precision Medicine: Hype or Hope?. Baylor University Medical Center Proceedings 28:3, pages 397-400.
Read now
Read now
Robert G. Mennel. (2015) Precision Medicine: Hype or Hoax?. Baylor University Medical Center Proceedings 28:3, pages 397-400.
Read now
Read now
Articles from other publishers (5)
Marios Spanakis, Athina E. Patelarou & Evridiki Patelarou. (2020) Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice. Journal of Personalized Medicine 10:3, pages 56.
Crossref
Crossref
Sami Morin-Ben Abdallah & Vera Hirsh. (2017) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology 7.
Crossref
Crossref
MAHESH G. KHARATMOL & DEEPALI M. JAGDALE. (2017) Targeting epidermal growth factor receptor: An important strategy in oncology. International Journal of Pharma and Bio Science 8:1.
Crossref
Crossref
Gregory R. Ott, Mangeng Cheng, Keith S. Learn, Jason Wagner, Diane E. Gingrich, Joseph G. Lisko, Matthew Curry, Eugen F. Mesaros, Arup K. Ghose, Matthew R. Quail, Weihua Wan, Lihui Lu, Pawel Dobrzanski, Mark S. Albom, Thelma S. Angeles, Kevin Wells-Knecht, Zeqi Huang, Lisa D. Aimone, Elizabeth Bruckheimer, Nathan Anderson, Jay Friedman, Sandra V. Fernandez, Mark A. Ator, Bruce A. Ruggeri & Bruce D. Dorsey. (2016) Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry 59:16, pages 7478-7496.
Crossref
Crossref
Hong Wu, Aoli Wang, Wei Zhang, Beilei Wang, Cheng Chen, Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu, Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang, Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu, Liang Chen & Qingsong Liu. (2015) Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget 6:31, pages 31313-31322.
Crossref
Crossref